Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Rockwell Automation (ROK) Price & Performance

Cassava Sciences IncTrade
Rockwell AutomationTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Rockwell Automation — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Rockwell Automation trades at $447 (market cap $48.33B). The key difference: Rockwell Automation is far larger — about 1012.1× Cassava Sciences Inc's market cap, and Rockwell Automation pays a 1.27% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAROK
Market Cap
$47.75M$48.33B
Sector
HealthIndustrials
52-Week High
$4.64$495.08
52-Week Low
$0.87$333.75
Enterprise Value
-$34.93M$51.46B
Dividend Yield
1.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Rockwell Automation

Rockwell Automation (ROK) trades at $441.04, down 0.17% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 49.09% gross margin and 13.38% net income margin, but elevated valuation ratios like a P/E of 41.3 suggest premium pricing. Q3 2026 results exceeded expectations, driven by organic sales growth and margin expansion, prompting raised full-year guidance.

The outlook is mixed: analyst consensus leans bullish with a $480.25 price target (30% buy ratings), but technical weakness and high valuation pose near-term risks. Key catalysts include sustained automation demand and cost management, while inflation and competitive pressures remain headwinds for shareholder returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Rockwell Automation

Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.

Read more on ROK